Harvard Apparatus Regenerative Technology Inc.
03/03/2026 | Press release | Distributed by Public on 03/03/2026 06:31
Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets' Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company's investor relations website at 2:15pm ET that day.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
[email protected]
Harvard Apparatus Regenerative Technology Inc. published this content on March 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 03, 2026 at 12:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]